^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IGFBP7 overexpression

    i
    Other names: IGFBP7, Insulin Like Growth Factor Binding Protein 7, IGFBP-7, MAC25, PSF, FSTL2, Insulin-Like Growth Factor-Binding Protein 7, Prostacyclin-Stimulating Factor, Tumor-Derived Adhesion Factor, PGI2-Stimulating Factor, IGF-Binding Protein 7, IGFBP-RP1, IBP-7, TAF, Insulin-Like Growth Factor Binding Protein 7, MAC25 Protein, Angiomodulin, IGFBP-7v, IGFBPRP1, RAMSVPS, AGM
    Entrez ID:
    3490
    1m
    Targeting IGF-IR improves neoadjuvant chemotherapy efficacy in breast cancers with low IGFBP7 expression. (PubMed, NPJ Precis Oncol)
    We report that low IGFBP7 gene expression identifies a subset of breast cancers for which the addition of ganitumab, an anti-IGF-1R monoclonal antibody, to neoadjuvant chemotherapy, substantially improved the pathological complete response rate compared to neoadjuvant chemotherapy alone...Furthermore, high IGFBP7 expression predicted increased distant metastasis risk. If our findings are confirmed, decisions to halt the development of IGF-1R targeting drugs, which were based on disappointing results of prior trials that did not use predictive biomarkers, should be reviewed.
    Journal
    |
    IGFBP7 (Insulin Like Growth Factor Binding Protein 7)
    |
    IGFBP7 overexpression
    |
    ganitumab (AMG 479)
    1m
    IGFBP7 regulates cell proliferation and migration through JAK/STAT pathway in gastric cancer and is regulated by DNA and RNA methylation. (PubMed, J Cell Mol Med)
    Western blotting analysis showed that the JAK1/2-specific inhibitor ruxolitinib could rescue alterations induced by IGFBP7 overexpression in GC cells...This study emphasizes the clinical relevance of IGFBP7 in GC and its influence on cell proliferation and migration via the JAK/STAT signalling pathway. This study also highlights the regulation of IGFBP7 in GC by DNA and m6A RNA methylation.
    Journal
    |
    MSI (Microsatellite instability) • JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7)
    |
    IGFBP7 overexpression
    |
    Jakafi (ruxolitinib)
    12ms
    Analysis of IGFBP7 expression characteristics in pan-cancer and its clinical relevance to stomach adenocarcinoma. (PubMed, Transl Cancer Res)
    IGFBP7 showed promise as a biomarker for prediction and prognosis in pan-cancer. IGFBP7 was found to be overexpressed in STAD, and its expression was closely associated with the clinical characteristics of STAD.
    Journal • Pan tumor
    |
    IGFBP7 (Insulin Like Growth Factor Binding Protein 7)
    |
    IGFBP7 overexpression
    over1year
    Crosstalk between Cancer Cells and Cancer-Associated Fibroblasts Mediated by TGF-β1-IGFBP7 Signaling Promotes the Progression of Infiltrative Gastric Cancer. (PubMed, Cancers (Basel))
    Moreover, IGFBP7 induced EMT in XGC-1. Therefore, our study clarified that in the tumor microenvironment, tumor-cell-derived TGF-β1 induces the appearance of the IGFBP7 CAF subgroup, and its higher IGFBP7 extracellular secretion level accelerates the progression of tumors.
    Journal
    |
    PDGFRB (Platelet Derived Growth Factor Receptor Beta) • TGFB1 (Transforming Growth Factor Beta 1) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7)
    |
    IGFBP7 overexpression
    over1year
    IGFBP‑rP1 affects the proliferation, apoptosis and macrophage polarization of endometrial cancer cells by regulating the PI3K/AKT pathway. (PubMed, Exp Ther Med)
    Overexpression of AKT in EC cells abolished the inhibitory effect of IGFBP-rP1 on M2 polarization. IGFBP-rP1 as an oncogenic factor inhibits M2 polarization of TAMs through PI3K/AKT signaling pathway and may be a potentially valuable target for EC therapy.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7)
    |
    AKT1 overexpression • IGFBP7 overexpression
    2years
    Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma. (PubMed, Cancer Med)
    IGFBP7 but not PDGFRA served an ideal prognostic marker and therapeutic target of glioma.
    Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7)
    |
    IDH wild-type • IGFBP7 overexpression • PDGFRA overexpression
    3years
    Physiological IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia. (PubMed, Blood Adv)
    In conclusion, IGFBP7 plays an oncogenic role in ALL by promoting the perdurance of IGF1R at the cell surface, prolonging insulin/IGFs stimulation. Preclinical data demonstrate that IGFBP7 is a valid target for antibody based therapeutic interventions in ALL.
    Journal
    |
    IGF1 (Insulin-like growth factor 1) • IRS1 (Insulin Receptor Substrate 1) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7)
    |
    IGFBP7 overexpression